Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Assets (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed Assets for 7 consecutive years, with $936.0 million as the latest value for Q4 2025.

  • Quarterly Assets rose 1.82% to $936.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $936.0 million through Dec 2025, up 1.82% year-over-year, with the annual reading at $936.0 million for FY2025, 1.82% up from the prior year.
  • Assets hit $936.0 million in Q4 2025 for BridgeBio Pharma, down from $998.2 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $1.1 billion in Q1 2021 to a low of $503.7 million in Q2 2023.
  • Historically, Assets has averaged $822.6 million across 5 years, with a median of $831.2 million in 2022.
  • Biggest five-year swings in Assets: crashed 41.59% in 2023 and later soared 68.26% in 2024.
  • Year by year, Assets stood at $1.0 billion in 2021, then crashed by 38.48% to $623.0 million in 2022, then dropped by 12.3% to $546.4 million in 2023, then skyrocketed by 68.26% to $919.3 million in 2024, then increased by 1.82% to $936.0 million in 2025.
  • Business Quant data shows Assets for BBIO at $936.0 million in Q4 2025, $998.2 million in Q3 2025, and $1.1 billion in Q2 2025.